REGENXBIO Inc. (RGNX) has a negative trailing P/E of -2.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 4.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -43.33%, forward earnings yield 24.15%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -7.8 | 1.76 | 3.03 | 106.75 | - |
| 2017 | -13.6 | -4.61 | 5.43 | 95.55 | - |
| 2018 | 15.4 | -0.07 | 3.02 | 7.03 | - |
| 2019 | -15.9 | 0.08 | 3.34 | 42.66 | - |
| 2020 | -15.2 | -0.98 | 4.48 | 10.94 | - |
| 2021 | 10.9 | -0.05 | 1.82 | 2.95 | - |
| 2022 | -3.5 | 0.01 | 1.90 | 8.68 | - |
| 2023 | -3.0 | 0.40 | 2.52 | 8.70 | - |
| 2024 | -1.7 | 0.07 | 1.47 | 4.59 | - |
| 2025 | -3.8 | 0.21 | 7.23 | 4.36 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.38 | $4.59M | $-62.97M | -1372.1% |
| 2017 | $-2.45 | $10.39M | $-73.17M | -704% |
| 2018 | $2.73 | $218.51M | $99.94M | 45.7% |
| 2019 | $-2.58 | $35.23M | $-94.73M | -268.9% |
| 2020 | $-2.98 | $154.57M | $-111.25M | -72% |
| 2021 | $2.91 | $470.35M | $127.84M | 27.2% |
| 2022 | $-6.50 | $112.72M | $-280.32M | -248.7% |
| 2023 | $-6.02 | $90.24M | $-263.49M | -292% |
| 2024 | $-4.59 | $83.33M | $-227.1M | -272.5% |
| 2025 | $-3.76 | $170.44M | $-193.88M | -113.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.15 | $-4.48 – $1.48 | $252.49M | $163.43M – $378.43M | 8 |
| 2027 | $-2.81 | $-7.21 – $0.90 | $297.14M | $189.88M – $509.72M | 5 |
| 2028 | $-1.40 | $-2.43 – $-0.34 | $489.54M | $285.32M – $785.38M | 4 |
| 2029 | $2.24 | $1.03 – $4.01 | $725.13M | $422.64M – $1.16B | 2 |
| 2030 | $6.21 | $2.84 – $11.08 | $977.85M | $569.93M – $1.57B | 2 |
